Literature DB >> 26045851

Sarcomatous transformation of EGFR and TP53 mutation-positive metastatic adenocarcinoma of the lungs, masquerading as a primary pleomorphic sarcoma of the proximal femur.

Midori Toda-Ishii1, Keisuke Akaike1, Aiko Kurisaki-Arakawa2, Atsushi Arakawa2, Kenta Mukaihara1, Yoshiyuki Suehara3, Tatsuya Takagi3, Kazuo Kaneko3, Takashi Yao2, Tsuyoshi Saito2.   

Abstract

We investigated a case of metastatic adenocarcinoma of the lungs at the left proximal femur, masquerading as a primary pleomorphic sarcoma. A 72-year-old woman presented with pain in her left thigh in conjunction with a mass that had been gradually growing over a few months. She was being treated with gefitinib for lung adenocarcinoma positive for the epidermal growth factor receptor (EGFR) mutation L858R, and had multiple bone metastases. The lung adenocarcinoma and metastases had stabilized with the treatment. The metastatic lesions in the bone had also received radiation; however, a tumor in the proximal femur kept growing despite treatment. A biopsy specimen from the proximal femur revealed the proliferation of spindle-shaped cells without an epithelial glandular component. The patient underwent en bloc resection of the proximal femur that was replaced by prosthesis. Histologically, the resected tumor was entirely composed of pleomorphic cells and tumor giant cells exhibiting no apparent glandular structures. Tumor cells were diffusely positive for p53 and focally positive for epithelial markers and EGFR, but were negative for thyroid transcription factor-1, suggesting an initial diagnosis of primary pleomorphic sarcoma. Genetic examination revealed mutations in EGFR and p53 that were of the same type as the lung tumor, leading to the final diagnosis of the femoral mass as a sarcomatous transformation of metastatic lung adenocarcinoma. However, secondary genetic alterations that might explain the acquired resistance to gefitinib could not be found in the proximal femoral tumor. The patient remains alive and the remaining lesions are well controlled.

Entities:  

Keywords:  EGFR; Lung adenocarcinoma; TP53; metastasis

Mesh:

Substances:

Year:  2015        PMID: 26045851      PMCID: PMC4440160     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

1.  Postradiation sarcoma of bone.

Authors:  A O SABANAS; D C DAHLIN; D S CHILDS; J C IVINS
Journal:  Cancer       Date:  1956 May-Jun       Impact factor: 6.860

2.  Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.

Authors:  Satoshi Watanabe; Takashi Sone; Tomoharu Matsui; Kenta Yamamura; Mayuko Tani; Akihito Okazaki; Koji Kurokawa; Yuichi Tambo; Hazuki Takato; Noriyuki Ohkura; Yuko Waseda; Nobuyuki Katayama; Kazuo Kasahara
Journal:  Lung Cancer       Date:  2013-09-05       Impact factor: 5.705

3.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

4.  EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy.

Authors:  Yih-Leong Chang; Chen-Tu Wu; Jin-Yuan Shih; Yung-Chie Lee
Journal:  Ann Surg Oncol       Date:  2011-03-16       Impact factor: 5.344

5.  Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.

Authors:  Chizuko Yamamoto; Yuji Basaki; Akihiko Kawahara; Kazutaka Nakashima; Masayoshi Kage; Hiroto Izumi; Kimitoshi Kohno; Hidetaka Uramoto; Kosei Yasumoto; Michihiko Kuwano; Mayumi Ono
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

6.  Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.

Authors:  Bryan C Fuchs; Tsutomu Fujii; Jon D Dorfman; Jonathan M Goodwin; Andrew X Zhu; Michael Lanuti; Kenneth K Tanabe
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

7.  Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma.

Authors:  Justine A Barletta; Sven Perner; A John Iafrate; Beow Y Yeap; Barbara A Weir; Laura A Johnson; Bruce E Johnson; Matthew Meyerson; Mark A Rubin; William D Travis; Massimo Loda; Lucian R Chirieac
Journal:  J Cell Mol Med       Date:  2009-08       Impact factor: 5.310

Review 8.  Radiation-induced sarcoma.

Authors:  S R Patel
Journal:  Curr Treat Options Oncol       Date:  2000-08

9.  Mutation of the p53 gene in postradiation sarcoma.

Authors:  H Nakanishi; Y Tomita; A Myoui; H Yoshikawa; K Sakai; Y Kato; T Ochi; K Aozasa
Journal:  Lab Invest       Date:  1998-06       Impact factor: 5.662

10.  Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.

Authors:  Barbara A Frederick; Barbara A Helfrich; Christopher D Coldren; Di Zheng; Dan Chan; Paul A Bunn; David Raben
Journal:  Mol Cancer Ther       Date:  2007-05-31       Impact factor: 6.261

View more
  4 in total

Review 1.  Histologic transformation in lung cancer: when one door shuts, another opens.

Authors:  Yuki Sato; Go Saito; Daichi Fujimoto
Journal:  Ther Adv Med Oncol       Date:  2022-10-14       Impact factor: 5.485

Review 2.  Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.

Authors:  Yi Shao; Dian-Sheng Zhong
Journal:  Int J Clin Oncol       Date:  2017-11-07       Impact factor: 3.402

3.  Prediction of clinical outcome and survival in soft-tissue sarcoma using a ten-lncRNA signature.

Authors:  Rong-Quan He; Qing-Jun Wei; Rui-Xue Tang; Wen-Jie Chen; Xia Yang; Zhi-Gang Peng; Xiao-Hua Hu; Jie Ma; Gang Chen
Journal:  Oncotarget       Date:  2017-05-22

Review 4.  Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.

Authors:  Fiorella Calabrese; Federica Pezzuto; Francesca Lunardi; Francesco Fortarezza; Sofia-Eleni Tzorakoleftheraki; Maria Vittoria Resi; Mariaenrica Tiné; Giulia Pasello; Paul Hofman
Journal:  Int J Mol Sci       Date:  2022-04-09       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.